Stock Analysis -Genmab A/S (GMAB)

Genmab A/S (GMAB), Denmark based company develops antibody therapeutics for the treatment of cancer and other diseases

Fundamental :
640M Shares

Last quarter EPS growth : +1283%
EPS rating of 84 (better than 84% of other Nasdaq stocks)
Last quarter Sales growth: + 596%

The company made a triple digit earnings acceleration in 3 out of last 4 quarters and triple digit sales acceleration in 2 out of last 3 quarters.

ROE : 19%
Cash Flow per share : $0.53
Debt : 0%
Research & Developments : 44.6% of sales

Management owns 2% with a new COO (Anthony Mancini) since March

Technical :
Second stage base (Flat Base; Buy point = $39).

Volume : 4.3 m shares (2.9 m average)

Market cap : $23.5 Billion

Moving averages : Last price above 10 weeks and 40 weeks moving averages.
Holding the 10 WMA since APRIL with only 2 weeks below it on below average volume (Institutional support)


Showing institutional accumulation in 20 out of 28 weeks since March low

Made 42% return since first stage base breakout (from a V shaped cup pattern) in May.